FDA Approves Asundexian for Secondary Stroke Prevention

Company Bayer Event Type FDA approval Modality Small molecule (oral) Asset Asundexian Target Factor XIa Disease Area Secondary prevention of ischemic stroke and high-risk TIA Summary Recovered source-gap item: Bayer announced November 10 US FDA approval of asundexian 50 mg with antiplatelet therapy after non-cardioembolic…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *